A change in just one letter in the code that makes up a cancer-causing gene can significantly affect how aggressive a tumor is or how well a patient with cancer responds to a particular therapy. A new, very precise gene-editing tool created by Weill Cornell Medicine investigators will enable scientists to study the impact of these specific genetic changes in preclinical models rather than being limited to more broadly targeted tactics, such as deleting the entire gene.

The tool was described in a study published Aug. 10 in Nature Biotechnology. Lukas Dow, an associate professor of biochemistry in medicine at Weill Cornell Medicine, and his colleagues genetically engineered mice to carry an enzyme that allows the scientists to change a single base or “letter” in the mouse’s genetic code. The enzyme can be turned on or off by feeding the mice doxycycline, an antibiotic, reducing the prospect of unintended genetic changes occurring over time. Investigators can also grow organoids – miniature versions of intestine, lung and pancreas tissue – from the mice, enabling even more molecular and biochemical studies of the impact of these precise genetic changes.

“We are excited about using this technology to try and understand the genetic changes that influence a patient’s response to cancer therapies,” said Dow, who is also a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

Dow noted that differences in a single base in a gene can have functional consequences. But most gene-editing tools currently available aim at larger targets like whole genes. Scientists can also use viruses to deliver genes with specific mutations, but this technique is limited to targeting specific tissues like the brain and liver, he said.  

“We’ve had good tools for a long time now to knock genes out or overexpress genes,” Dow said. “But we have not had good ways to create the single-base mutations that we see in patient’s tumors.”

The mouse model allows them to study the effects of the changes on tumors and determine which therapies work best for those with a particular mutation. Organoids derived from the mice enable detailed experiments in tissues that scientists could not easily target with virus-based approaches.  

“One mouse model allows you to do two things: test the effects of a mutation in cancer initiation, progression, or treatment response in mice and take a closer look at the associated molecular or biochemical changes using organoids,” he said.

Dow and his team, including co-first authors Alyna Katti, a former graduate student, and Adrián Vega-Pérez, a postdoctoral associate, are currently using this new technology to identify the effects of single-base mutations in lung, colon and pancreatic cancer. Their genetically engineered mice will be available to other researchers, which may help accelerate progress toward personalized cancer treatment.  

“We are making the technology available to other people in the field so they can use it to study their mutations of interest,” Dow said. “If we can learn the genetic underpinnings of what causes tumor formation and why patients have different outcomes, that may help us develop new drugs or select the best drugs for a particular patient.”

Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. For this information, see profile for Dow.

Bridget Kuehn is a freelance writer for Weill Cornell Medicine.